CLEVELAND, Ohio — Researchers at Case Western Reserve University School of Medicine and MetroHealth System have developed a ...
Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Background: The signal transducer and activator of transcription 3 ...
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been ...
Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14. Background: Elranatamab ...
Dr. Gabriel Mannis from Stanford University and Dr. Gail Roboz from Weill Cornell Medicine discussed the evolving treatment ...
Please provide your email address to receive an email when new articles are posted on . Nearly 30,000 new cases of diffuse large B-cell lymphoma are diagnosed annually in the United States. Of these, ...
The recent FDA approval of teclistamab (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzelex Faspro) marks a major ...
Clinical trials provide patients with relapsed or treatment-resistant lymphoma access to emerging therapies, making conversations with providers essential, according to Dr. Jennif ...
Transcription: Colleen Moretti: What is relapsed/refractory multiple myeloma? How does it differ from typical disease? Dr. Saad Usmani: Relapsed and/or refractory myeloma is myeloma that has come back ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results